May 17, 2023

FendX Technologies Inks Worldwide Distribution Agreement For Anti-Pathogen Spray

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a member of the community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

This morning, FendX Technologies Inc. (CSE: FNDX) announced important news regarding an exclusive worldwide licensing agreement for the development of a spray coating formulation that  repels and kills pathogens, reducing contamination on high-touch surfaces. FendX Technologies Inc. is a nanotechnology company focused on developing innovative solutions to enhance safety by reducing the spread of pathogens. The company specializes in surface protection coatings and offers a range of products designed to repel and eliminate pathogens on various surfaces. FendX's nanotechnology portfolio includes a protective film called REPELWRAP™ that is in early-stage scale-up manufacturing and newly licensed spray coating technology. By leveraging cutting-edge research and collaboration with McMaster University and with other leading-edge partners, FendX aims to provide effective and accessible solutions for reducing contamination and promoting safer environments.

This is a paid advertisement by FendX Technologies Inc.

Key highlights:

  • FendX Technologies has signed an exclusive worldwide license agreement with McMaster University for a spray coating formulation.
  • The spray coating repels and kills pathogens, reducing contamination on high-touch surfaces.
  • The license agreement grants FendX the rights to develop and sell nano-spray coating products with pathogen-repelling and killing properties.
  • McMaster lab testing shows a significant reduction in adhesion and transfer of pathogens, with up to 99.99% reduction in adhesion for MRSA and 99.96% reduction for the bacterial virus Phi6.
  • Killing activity was 99.98% for both MRSA and Pseudomonas aeruginosa
  • The spray formulation complements FendX's existing nanotechnology portfolio, expanding potential market opportunities beyond industrial and commercial applications.
  • The spray nanotechnology has been published in two peer-reviewed journals authored by McMaster scientists, showcasing its effectiveness.

FendX is a nanotechnology company focused on developing products to reduce the spread of pathogens, including a protective film (REPELWRAP™) and the new spray coating.The company collaborates with McMaster University and holds an exclusive worldwide license for their technology and intellectual property portfolio.

FendX Technologies Inc. General Disclaimer

This article contains certain forward-looking statements within the meaning of Canadian securities legislation (the “Forward-looking Statements”), including with respect to: the plans of FNDX; expectations regarding industry trends, including with respect to the antimicrobial surface market, overall market growth rates and FNDX’s growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of FNDX’s business and operations; FNDX’s expectations regarding revenues, expenses and anticipated cash needs; the intention to grow FNDX’s business and operations; the expected timing and completion of FNDX’s near‑term objectives; laws and regulations and any amendments thereto applicable to FNDX; FNDX’s competitive advantages and business strategies; FNDX’s future product offerings; FNDX’s research and development initiatives and expected results thereof; FNDX’s growing patent portfolio; FNDX’s ability to enter into distribution, manufacturing and other business relationships; the potential of FNDX’s technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that FNDX’s technology will bring significant value in controlling the spread of surface borne infectious diseases; that FNDX’s technology could be a key weapon to contribute in the battle against the growing global threat of infectious disease transmission; that FNDX’s technology could be deployed all over the world and it could save human lives; that spread of infectious disease is a deadly problem which is getting worse; that for businesses and governments looking to mitigate the spread of pathogens, FNDX’s nanotechnology could be part of the answer; if commercialized, FNDX’s technology could address the urgent need for innovative solutions to help control the spread of pathogens on surfaces – especially in healthcare; FNDX’s proprietary REPELWRAP™ film could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; FNDX’s nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if FNDX can successfully adapt their technology; FNDX’s intention to initially target REPELWRAPTM film towards healthcare settings and high traffic public touchpoints; that as FNDX continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, sports and entertainment, hospitality, and education sectors; the growing global commitment to reduce the spread of pathogens; and that REPELWRAP™ film will provide additional protection to current disinfecting practices to control the spread of pathogens. Although FNDX believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,” “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. FNDX cautions that forward-looking statements are based on the beliefs, estimates and opinions of FNDX’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement and Collaborative Research Agreement between FNDX and McMaster University and maintaining the License in good standing; inability of McMaster University to satisfy the terms under the License Agreement and Collaborative Research Agreement; completion of scale-up and development of a commercial product; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; changes and restrictions due to legal and regulatory requirements; dependence on each product’s acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of FNDX’s directors and officers; management’s efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of FNDX’s common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavourable research about FNDX; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in FNDX’s final prospectus dated January 31, 2023 under the heading “Risk Factors” and other filings, publicly available through the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) at The reader is urged to refer to FNDX’s prospectus and other filings, publicly available through SEDAR at for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, FNDX undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for FNDX to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any Forward-looking Statement. Any Forward-looking Statements contained in this article are expressly qualified in their entirety by this cautionary statement.

While the information contained in this article is believed to be accurate, FNDX expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this article or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this article are intended to be, nor shall be deemed to be, representations or warranties of FNDX. Where the information is from third-party sources, the information is from sources believed to be reliable, but FNDX has not independently verified any of such information contained herein.

This article is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any shares.


FendX Technologies Inc. is a sponsor of Medical Sponsors of pay for one year of coverage in order to increase awareness of a product, service, person, company or idea. Coverage of sponsor companies is for information; illustrative purposes only.  strives to increase awareness of companies while remaining as objective as possible. Nothing contained in articles; written interviews on is an offer/solicitation to Buy or Sell securities. Readers are strongly advised to consult with their own licensed or registered financial advisors before making investment decisions. Micro-cap companies are highly speculative, investors in its securities could experience up to 100% loss of invested funds.


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on for important risk disclosures. It’s your money and your responsibility.